Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, with a pipeline focused on dermatology and rheumatology indications. The company has transitioned from commercial operations (divested dermatology assets in 2022) to pure-play R&D, with lead programs including ATI-1777 (soft tissue sarcoma) and ATI-2138 (autoimmune conditions). Stock performance is driven entirely by clinical trial readouts, regulatory milestones, and cash runway visibility rather than operational fundamentals.
Aclaris operates as a clinical-stage biotech with no meaningful current revenue generation. The business model relies on advancing drug candidates through Phase 1/2/3 trials, securing regulatory approvals, and either commercializing products independently or licensing/partnering with larger pharmaceutical companies for milestone payments and royalties. The company's 85% gross margin reflects minimal cost of goods sold on residual revenue streams. Value creation occurs through successful clinical data releases that increase probability of approval and peak sales estimates, enabling equity financing at higher valuations or strategic partnerships with upfront/milestone payments. Operating losses of -758% margin are typical for clinical-stage biotechs burning cash on R&D without offsetting revenue.
Clinical trial data releases (Phase 1/2/3 readouts) showing efficacy, safety, and differentiation versus standard of care
FDA regulatory interactions including IND clearances, Fast Track designations, Breakthrough Therapy designations, and approval decisions
Strategic partnership announcements with larger pharma companies providing validation and non-dilutive capital
Equity financing events and cash runway updates (current ratio of 3.92 suggests 12-18 months runway based on typical burn rates)
Competitive clinical data from rival programs targeting similar indications
Key opinion leader presentations at medical conferences (ASH, ASCO, AAD) providing clinical context
Binary clinical trial risk where single Phase 2/3 failures can eliminate 50-90% of market capitalization overnight, with ATI-1777 and ATI-2138 representing concentrated pipeline risk
Regulatory approval uncertainty with FDA requiring increasingly robust safety/efficacy data, particularly for competitive indications with existing treatment options
Capital markets dependency requiring periodic equity raises that dilute existing shareholders, with biotech IPO/follow-on windows subject to market sentiment cycles
Large pharmaceutical companies with significantly greater resources developing competing mechanisms of action for overlapping indications
First-mover disadvantage if competitors achieve regulatory approval first and establish standard of care, making differentiation and market access more difficult
Patent expiration risk on key composition of matter patents potentially enabling generic competition before achieving return on R&D investment
Cash burn rate of approximately $50-60M annually (estimated from -$50M operating cash flow TTM) creates ongoing dilution risk and potential need for financing at unfavorable terms
Current ratio of 3.92 suggests adequate near-term liquidity but limited runway beyond 2027 without additional capital, creating pressure to achieve partnership or positive clinical data
Negative tangible book value typical for clinical biotechs means liquidation value is minimal, making equity holders dependent entirely on pipeline success
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones rather than economic conditions. However, financing environment (ability to raise capital via equity or debt) becomes more challenging during recessions when risk appetite declines and biotech indices underperform. Patient enrollment in trials may see modest impacts during severe downturns but generally remains stable.
Rising interest rates negatively impact valuation through two mechanisms: (1) higher discount rates applied to distant future cash flows from potential product approvals reduce NPV of pipeline assets, and (2) increased competition from risk-free rates makes speculative biotech investments less attractive relative to fixed income. Clinical-stage biotechs with no debt have minimal direct interest expense impact but face compressed valuation multiples. The company's 0.02 debt/equity ratio means financing costs are negligible, but equity financing becomes more dilutive as valuations compress.
Minimal direct credit exposure given negligible debt levels and no meaningful accounts receivable from commercial operations. However, access to capital markets for equity financing is critical for survival, and credit market stress often correlates with biotech financing windows closing. Venture debt availability as non-dilutive financing option also tightens during credit contractions.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from clinical trial success, with potential for multi-bagger returns if pipeline assets achieve approval but high probability of significant losses on trial failures. Recent 77% six-month return reflects momentum following positive catalysts. Not suitable for value or income investors given negative earnings, no dividends, and valuation based entirely on discounted future cash flows from unapproved products.
high - Clinical-stage biotechs exhibit extreme volatility with 30-50% single-day moves common around data releases. Small market cap of $400M amplifies price swings on modest volume changes. Beta likely exceeds 1.5-2.0 relative to broader market, with idiosyncratic risk dominating systematic risk. Options markets typically price elevated implied volatility around known catalyst dates.
